This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
No cases of virologic failure observed with ABT-493 plus ABT-530
SAN DIEGO — An investigative combination of two drugs helped patients infected with hepatitis C virus (HCV) across genotypes 1, 2, 3.4, 5, and 6 achieve sustained virologic responses, researchers reported here.
No cases of virologic failure were observed in the 8-week courses of ABT-493 plus ABT-530 in noncirrhotic patients infected with genotypes 1, 2 and 3, and no virologic failures were observed among patients with genotypes 4, 5 and 6 who were treated in a 12-week course, according to Tarek Hassanein, MD, of the Southern California GI and Liver Centers/UC San Diego Health System, David Wyles, MD, of the University of California San Diego, and colleagues.
In multiple presentations at the annual Digestive Disease Week (DDW), they described preliminary studies using the pangenotypic agents against the six different genotypes of HCV.
Read more…http://www.medpagetoday.com/MeetingCoverage/DDW/58121